Phase I study using crenolanib to target PDGFR kinase in children and young adults with newly diagnosed DIPG or recurrent high-grade glioma, including DIPG is a research paper published in Neuro-Oncology Advances (2021). On theSindex it has a DataRank of 0. It has been cited 20 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Cancer Institute
Grant: P30 CA021765
St. Jude Cancer Center Support
Grant: P01CA096832
National Institutes of Health
Grant: 5P01CA096832-07
Normal &Neoplastic Growth in the Brain
National Institutes of Health
Grant: 3P30CA021765-41S2
Cancer Center Support Grant (CCSG)
Arog Pharmaceuticals
American Lebanese Syrian Associated Charities
FWCI
1.63
Citation Percentile
0.8%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals
Additional file 1 of Convergent evolution and multi-wave clonal invasion in H3 K27-altered diffuse midline gliomas treated with a PDGFR inhibitor
Additional file 1 of Convergent evolution and multi-wave clonal invasion in H3 K27-altered diffuse midline gliomas treated with a PDGFR inhibitor
Additional file 2 of Convergent evolution and multi-wave clonal invasion in H3 K27-altered diffuse midline gliomas treated with a PDGFR inhibitor
Additional file 2 of Convergent evolution and multi-wave clonal invasion in H3 K27-altered diffuse midline gliomas treated with a PDGFR inhibitor